BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

BioMarin Pharmaceutical (NASDAQ: BMRN) has scheduled its first quarter 2025 financial results conference call and webcast for Thursday, May 1, 2025, at 4:30 p.m. ET. The event will be hosted by Alexander Hardy, President and Chief Executive Officer, who will discuss Q1 2025 financial performance and provide a business update.

Participants can join via phone using U.S./Canada dial-in (888-596-4144) or International dial-in (646-968-2525) with Conference ID 4327591. A live audio webcast will be available through BioMarin's investor website. A replay will be accessible for one week following the call.

News Market Reaction

+0.60%

1 alert

+0.60% News Effect

On the day this news was published, BMRN gained 0.60%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

04/17/2025 - 09:00 AM

SAN RAFAEL, Calif., April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update.

Dial-in Number
U.S. / Canada Dial-in Number: 888-596-4144
International Dial-in Number: 646-968-2525
Conference Call ID: 4327591

U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 4327591

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin
BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com.